IDA blend vs Syria: Cause of death, by non-communicable diseases, female
IDA blend
44.6%
in 2021
Syria
80.5%
in 2021
IDA blend rank
39th
Syria rank
36th
Cause of death, by non-communicable diseases, female over time
- IDA blend
- Syria
How they compare
Syria currently reports 80.5% against 44.6% in IDA blend, a difference of 35.9%.
That makes Syria's figure about 1.8 times IDA blend's.
Across all 6 years both countries report, Syria has been ahead every year.
IDA blend ranks 39th and Syria ranks 36th of 47 groups.
Syria has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | IDA blend | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 29.1% | 82.1% | 53.0% | Syria |
| 2010s | 41.0% | 75.7% | 34.6% | Syria |
| 2020s | 44.6% | 81.7% | 37.2% | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, female, IDA blend or Syria?
- Syria, at 80.5% against 44.6% in IDA blend as of 2021.
- What is the difference in cause of death, by non-communicable diseases, female between IDA blend and Syria?
- 35.9%, with Syria ahead.
- How many years of comparable data are there for IDA blend and Syria?
- 6 years are reported by both, from 2000 to 2021.
- How do IDA blend and Syria rank globally for cause of death, by non-communicable diseases, female?
- IDA blend ranks 39th and Syria ranks 36th of 47 groups.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, female (% of total female deaths). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of female deaths due to non-communicable diseases divided by number of all female deaths, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.